<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312520</url>
  </required_header>
  <id_info>
    <org_study_id>0020020166</org_study_id>
    <nct_id>NCT00312520</nct_id>
  </id_info>
  <brief_title>Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy</brief_title>
  <official_title>The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society for Pediatric Dermatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if pulse steroids are more efficacious and safer&#xD;
      than the standard treatment with oral corticosteroids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently there is no prospective study in hemangioma patients answering critical questions&#xD;
      such as: which type of steroid should be used,how much should we use and for how long. This&#xD;
      study is an investigator blinded study with two arms:one arm is receiving standard treatment&#xD;
      with daily oral corticosteroids and the other is receiving intravenous pulse corticosteroids&#xD;
      daily for 3 days, monthly for 3 months. The main outcome of the study is assess the efficacy&#xD;
      of each treament modality as the percentage improvement in the hemangioma's appearance. The&#xD;
      secondary outcomes are the safety profiles of the two drugs and the changes in the&#xD;
      angiogenesis markers as a result of treatment intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2002</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent improvement in the appearance of hemangioma</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of side-effects experienced by the patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the angiogenesis markers</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Hemangiomas</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  problematic facial hemangiomas (periorbital/facial hemangiomas with potential visual&#xD;
             obstruction, large/dysfiguring hemangiomas)&#xD;
&#xD;
          -  1-4 months of age&#xD;
&#xD;
          -  signed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal to participate&#xD;
&#xD;
          -  age &gt; 4 months&#xD;
&#xD;
          -  complicated nonvisible hemangiomas&#xD;
&#xD;
          -  congenital heart disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>4 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Pope, MD, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 6, 2006</study_first_submitted>
  <study_first_submitted_qc>April 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2006</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Elena Pope</investigator_full_name>
    <investigator_title>Head, Section of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

